BEVERLY HILLS, Calif.,
June 21, 2021 /PRNewswire/ -- GT
Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a
clinical stage immuno-oncology company focused on developing
innovative therapeutics based on the Company's proprietary natural
killer (NK) cell engager (TriKE™) protein biologic technology
platform, today announced that Dr. Jeffrey
S. Miller will be giving an update on the progress of the
GTB-3550 TriKE™ Phase I trial accompanying the Company's corporate
update presentation at the upcoming Raymond James Human Health
Innovation Conference on Tuesday, June 22,
2021 at 11:20 AM ET.
A live webcast of the event will be available by visiting the
"Presentations" page in the Investors section of GT Biopharma's
website at www.gtbiopharma.com/news-media/presentations. A replay
of the webcast will be archived for 30 days following the
presentation.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company
focused on the development and commercialization of immuno-oncology
therapeutic products based on our proprietary TriKE™ NK cell
engager platform. Our TriKE™ platform is designed to harness
and enhance the cancer killing abilities of a patient's immune
system's natural killer cells (NK cells). GT Biopharma has an
exclusive worldwide license agreement with the University of Minnesota to further develop and
commercialize therapies using TriKE™ technology. For more
information, please visit gtbiopharma.com.
Investor Contact:
Brendan
Payne
Client Lead
Stern Investor Relations, Inc.
brendan.payne@sternir.com
212-362-1200
Investor and Media Relations Contact
David Castaneda
David@gtbiopharma.com
414-351-9758
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dr-jeffrey-s-miller-to-present-on-progress-of-gtb-3550-trike-phase-i-trial-accompanying-gt-biopharmas-company-presentation-at-raymond-james-human-health-innovation-conference-301316040.html
SOURCE GT Biopharma, Inc.